The partnership employs KineMed’s new dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
KineMed president, co-founder and chief science officer Marc Hellerstein said the company is happy to announce the extension of this ongoing partnership in an important area of medicine that affects so many Americans.
"Our translational biomarker platform targets the metabolic processes and pathways that play a pathogenic role in disorders such as diabetes," Hellerstein said.
"This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes.
"We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials."
KineMed has developed a proprietary biomarker platform technology with broad applications in drug development and medical diagnostics.